Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 128 full-time employees. The company went IPO on 2019-06-19. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The firm is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Follow-Up Questions
Qui est le CEO de Stoke Therapeutics Inc ?
Dr. Edward Kaye est le Chief Executive Officer de Stoke Therapeutics Inc, il a rejoint l'entreprise depuis 2017.
Quelle est la performance du prix de l'action STOK ?
Le prix actuel de STOK est de $23.5, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Stoke Therapeutics Inc ?
Stoke Therapeutics Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Stoke Therapeutics Inc ?
La capitalisation boursière actuelle de Stoke Therapeutics Inc est de $1.2B
Est-ce que Stoke Therapeutics Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 11 analystes ont établi des notations d'analystes pour Stoke Therapeutics Inc, y compris 6 achat fort, 9 achat, 2 maintien, 0 vente et 6 vente forte
